297 related articles for article (PubMed ID: 34865945)
1. Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance.
Nijstad AL; Barnett S; Lalmohamed A; Bérénos IM; Parke E; Carruthers V; Tweddle DA; Kong J; Zwaan CM; Huitema ADR; Veal GJ
Eur J Cancer; 2022 Mar; 164():137-154. PubMed ID: 34865945
[TBL] [Abstract][Full Text] [Related]
2. Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens.
Veal GJ; Errington J; Sastry J; Chisholm J; Brock P; Morgenstern D; Pritchard-Jones K; Chowdhury T
Cancer Chemother Pharmacol; 2016 Apr; 77(4):685-92. PubMed ID: 26875154
[TBL] [Abstract][Full Text] [Related]
3. Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom.
Barnett S; Kong J; Makin G; Veal GJ
Br J Clin Pharmacol; 2021 Feb; 87(2):256-262. PubMed ID: 32519769
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Yaniv I; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chan GCF; Ruud E; Schroeder H; Beck Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
Lancet Oncol; 2018 Dec; 19(12):1617-1629. PubMed ID: 30442501
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review.
Yasuda H; Yasuda M; Komatsu N
Cancer Sci; 2021 Jul; 112(7):2607-2624. PubMed ID: 33938097
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy in newborns and preterm babies.
Veal GJ; Boddy AV
Semin Fetal Neonatal Med; 2012 Aug; 17(4):243-248. PubMed ID: 22464845
[TBL] [Abstract][Full Text] [Related]
8. Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients.
Barnett S; Hellmann F; Parke E; Makin G; Tweddle DA; Osborne C; Hempel G; Veal GJ
Eur J Cancer; 2022 Mar; 164():127-136. PubMed ID: 34657763
[TBL] [Abstract][Full Text] [Related]
9. Topotecan in combination chemotherapy.
Rowinsky EK; Kaufmann SH
Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-11-S20-26. PubMed ID: 9425957
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
[TBL] [Abstract][Full Text] [Related]
11. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
Gkotzamanidou M; Papadimitriou CA
Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.
Duong JK; Veal GJ; Nath CE; Shaw PJ; Errington J; Ladenstein R; Boddy AV
Br J Clin Pharmacol; 2019 Jan; 85(1):136-146. PubMed ID: 30261554
[TBL] [Abstract][Full Text] [Related]
13. Tandem high-dose chemotherapy with autologous stem cell rescue for stage M high-risk neuroblastoma: Experience using melphalan/etoposide/carboplatin and busulfan/melphalan regimens.
Kato S; Kubota Y; Watanabe K; Hogetsu K; Arakawa Y; Koh K; Takita J; Hiwatari M
Pediatr Transplant; 2020 Nov; 24(7):e13772. PubMed ID: 32543778
[TBL] [Abstract][Full Text] [Related]
14. Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers.
Elborai Y; Hafez H; Moussa EA; Hammad M; Hussein H; Lehmann L; Elhaddad A
Pediatr Transplant; 2016 Mar; 20(2):284-9. PubMed ID: 26614402
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): a phase I study of the Pediatric Blood and Marrow Transplant Consortium.
Sandler ES; Hagg R; Coppes MJ; Mustafa MM; Gamis A; Kamani N; Wall D
Med Pediatr Oncol; 2000 Oct; 35(4):403-9. PubMed ID: 11025470
[TBL] [Abstract][Full Text] [Related]
16. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
Paci A; Veal G; Bardin C; Levêque D; Widmer N; Beijnen J; Astier A; Chatelut E
Eur J Cancer; 2014 Aug; 50(12):2010-9. PubMed ID: 24889915
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin therapeutic monitoring in preterm and full-term neonates.
Veal GJ; Errington J; Hayden J; Hobin D; Murphy D; Dommett RM; Tweddle DA; Jenkinson H; Picton S
Eur J Cancer; 2015 Sep; 51(14):2022-30. PubMed ID: 26232270
[TBL] [Abstract][Full Text] [Related]
18. Generation of evidence-based carboplatin dosing guidelines for neonates and infants.
Barnett S; Makin G; Tweddle DA; Osborne C; Veal GJ
Br J Cancer; 2023 Nov; 129(11):1773-1779. PubMed ID: 37816842
[TBL] [Abstract][Full Text] [Related]
19. Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.
Kersting G; Willmann S; Würthwein G; Lippert J; Boos J; Hempel G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):397-405. PubMed ID: 21789689
[TBL] [Abstract][Full Text] [Related]
20. Options for first- and second-line therapy in small cell lung cancer--a workshop discussion.
Thatcher N; Eckardt J; Green M
Lung Cancer; 2003 Aug; 41 Suppl 4():S37-41. PubMed ID: 14565514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]